NO995006L - Nye forbindelser - Google Patents
Nye forbindelserInfo
- Publication number
- NO995006L NO995006L NO995006A NO995006A NO995006L NO 995006 L NO995006 L NO 995006L NO 995006 A NO995006 A NO 995006A NO 995006 A NO995006 A NO 995006A NO 995006 L NO995006 L NO 995006L
- Authority
- NO
- Norway
- Prior art keywords
- new connections
- compounds
- processes
- formula
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- DSBOPXOKGKIRSG-UHFFFAOYSA-N pyrrolo[3,4-d]pyrimidine-2,4-dione Chemical class O=C1NC(=O)C2=CN=CC2=N1 DSBOPXOKGKIRSG-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
Abstract
Farmasøytisk nyttige pyra2o]o[3,4-d]pyrimidindionforbindelser av formel (I) w / N-R (D fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende slike forbindelser, og deres anvendelse for behandling av forskjellige sykdommer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9701398A SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Novel compounds |
PCT/SE1998/000640 WO1998046606A1 (en) | 1997-04-15 | 1998-04-07 | Novel compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
NO995006D0 NO995006D0 (no) | 1999-10-14 |
NO995006L true NO995006L (no) | 1999-10-14 |
Family
ID=20406576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO995006A NO995006L (no) | 1997-04-15 | 1999-10-14 | Nye forbindelser |
Country Status (21)
Country | Link |
---|---|
US (1) | US6028074A (no) |
EP (1) | EP0975636B1 (no) |
JP (1) | JP2001520645A (no) |
KR (1) | KR20010006350A (no) |
CN (1) | CN1259951A (no) |
AT (1) | ATE245648T1 (no) |
AU (1) | AU733066B2 (no) |
BR (1) | BR9808540A (no) |
CA (1) | CA2286078A1 (no) |
DE (1) | DE69816608T2 (no) |
EE (1) | EE9900465A (no) |
HU (1) | HUP0002104A3 (no) |
ID (1) | ID22746A (no) |
IL (1) | IL132153A0 (no) |
IS (1) | IS5198A (no) |
NO (1) | NO995006L (no) |
PL (1) | PL336230A1 (no) |
SE (1) | SE9701398D0 (no) |
SK (1) | SK135699A3 (no) |
TR (1) | TR199902538T2 (no) |
WO (1) | WO1998046606A1 (no) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9801399D0 (sv) | 1998-04-21 | 1998-04-21 | Astra Pharma Prod | Method and apparatus for filling containers |
GC0000177A (en) * | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
US6875786B2 (en) | 2001-03-01 | 2005-04-05 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
IL160307A0 (en) | 2001-08-31 | 2004-07-25 | Univ Rockefeller | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
MY142390A (en) | 2002-05-22 | 2010-11-30 | Glaxosmithkline Llc | 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
TW200526638A (en) | 2003-10-22 | 2005-08-16 | Smithkline Beecham Corp | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline |
EP1901701A4 (en) * | 2005-05-24 | 2012-05-02 | David M Ott | BODY CARE AND MEDICAL PRODUCTS WITH JOINED SULFUR ORGANIC GROUPS |
BRPI0611095B8 (pt) | 2005-06-06 | 2021-05-25 | Intracellular Therapies Inc | compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos |
US9255099B2 (en) | 2006-06-06 | 2016-02-09 | Intra-Cellular Therapies, Inc. | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors |
US9198924B2 (en) | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
EP2240028B1 (en) * | 2007-12-06 | 2016-07-20 | Intra-Cellular Therapies, Inc. | Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical |
ES2436780T3 (es) | 2007-12-06 | 2014-01-07 | Takeda Pharmaceutical Company Limited | Compuestos orgánicos |
AU2009322899A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2358204B1 (en) | 2008-12-06 | 2015-08-05 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. |
SG171777A1 (en) * | 2008-12-06 | 2011-07-28 | Intra Cellular Therapies Inc | Organic compounds |
EP2358723B1 (en) | 2008-12-06 | 2015-05-13 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors |
EA201170773A1 (ru) | 2008-12-06 | 2012-01-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
CN102231953A (zh) | 2008-12-06 | 2011-11-02 | 细胞内治疗公司 | 有机化合物 |
WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
PE20120764A1 (es) | 2009-03-23 | 2012-06-27 | Glenmark Pharmaceuticals Sa | Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 |
SI2411395T1 (sl) | 2009-03-23 | 2013-07-31 | Glenmark Pharmaceuticals S.A. | Furopirimidindionski derivati kot TRPA1 modulatorji |
JP5657638B2 (ja) * | 2009-03-23 | 2015-01-21 | グレンマーク ファーマシューティカルズ, エセ.アー. | Trpa1調節因子としての縮合ピリミジンジオン誘導体 |
US8623880B2 (en) | 2009-03-23 | 2014-01-07 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
EP3127427B1 (en) | 2009-05-29 | 2020-01-08 | Novartis Ag | Methods of administration of thrombopoietin agonist compounds |
EP2461673A4 (en) | 2009-08-05 | 2013-08-07 | Intra Cellular Therapies Inc | NEW REGULATOR PROTEINS AND HEMMER |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
JP5894148B2 (ja) | 2010-05-31 | 2016-03-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
JP5911854B2 (ja) | 2010-05-31 | 2016-04-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
JP6051210B2 (ja) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
AU2013273118B2 (en) | 2012-06-08 | 2015-11-05 | Glenmark Pharmaceuticals S.A. | Amides of 2-amino-4-arylthiazole compounds and their salts |
US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
ES2717688T3 (es) | 2013-03-15 | 2019-06-24 | Intra Cellular Therapies Inc | Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP |
KR102240326B1 (ko) | 2013-03-15 | 2021-04-13 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
WO2015106032A1 (en) | 2014-01-08 | 2015-07-16 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
EP3157926B1 (en) | 2014-06-20 | 2019-05-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP3193878B1 (en) | 2014-09-17 | 2021-01-06 | Intra-Cellular Therapies, Inc. | 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns) |
KR102562576B1 (ko) | 2014-12-06 | 2023-08-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
BR112017012007B1 (pt) | 2014-12-06 | 2022-11-01 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
EP3475281A1 (en) * | 2016-06-23 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
EP3509589B1 (en) | 2016-09-12 | 2021-11-17 | Intra-Cellular Therapies, Inc. | Novel uses |
US11839614B2 (en) | 2018-01-31 | 2023-12-12 | Intra-Cellular Therapies, Inc. | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58500966A (ja) * | 1981-04-22 | 1983-06-09 | ビイク グルデン ロンベルク ヒエ−ミツシエ フアブリ−ク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 新規ピラゾロ〔3,4−d〕ピリミジン、その製法及びこれを含有する医薬品 |
US4603203A (en) * | 1983-12-14 | 1986-07-29 | Takeda Chemical Industries, Ltd. | 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof |
EP0237289A3 (en) * | 1986-03-14 | 1988-07-27 | Takeda Chemical Industries, Ltd. | Pyrazolo [3,4-d] pyrimidine derivatives, their production and use |
TW444018B (en) * | 1992-12-17 | 2001-07-01 | Pfizer | Pyrazolopyrimidines |
PL175831B1 (pl) * | 1992-12-17 | 1999-02-26 | Pfizer | Pochodna pirazolu |
-
1997
- 1997-04-15 SE SE9701398A patent/SE9701398D0/xx unknown
-
1998
- 1998-04-07 PL PL98336230A patent/PL336230A1/xx unknown
- 1998-04-07 TR TR1999/02538T patent/TR199902538T2/xx unknown
- 1998-04-07 EE EEP199900465A patent/EE9900465A/xx unknown
- 1998-04-07 SK SK1356-99A patent/SK135699A3/sk unknown
- 1998-04-07 AT AT98917859T patent/ATE245648T1/de not_active IP Right Cessation
- 1998-04-07 KR KR1019997009435A patent/KR20010006350A/ko not_active Application Discontinuation
- 1998-04-07 EP EP98917859A patent/EP0975636B1/en not_active Expired - Lifetime
- 1998-04-07 ID IDW991207A patent/ID22746A/id unknown
- 1998-04-07 AU AU70909/98A patent/AU733066B2/en not_active Ceased
- 1998-04-07 WO PCT/SE1998/000640 patent/WO1998046606A1/en active IP Right Grant
- 1998-04-07 IL IL13215398A patent/IL132153A0/xx unknown
- 1998-04-07 CA CA002286078A patent/CA2286078A1/en not_active Abandoned
- 1998-04-07 CN CN98806075A patent/CN1259951A/zh active Pending
- 1998-04-07 JP JP54380398A patent/JP2001520645A/ja not_active Ceased
- 1998-04-07 BR BR9808540-9A patent/BR9808540A/pt not_active IP Right Cessation
- 1998-04-07 DE DE69816608T patent/DE69816608T2/de not_active Expired - Fee Related
- 1998-04-07 HU HU0002104A patent/HUP0002104A3/hu unknown
- 1998-08-07 US US09/068,304 patent/US6028074A/en not_active Expired - Fee Related
-
1999
- 1999-09-27 IS IS5198A patent/IS5198A/is unknown
- 1999-10-14 NO NO995006A patent/NO995006L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EE9900465A (et) | 2000-04-17 |
BR9808540A (pt) | 2000-05-23 |
ID22746A (id) | 1999-12-09 |
IL132153A0 (en) | 2001-03-19 |
DE69816608D1 (de) | 2003-08-28 |
PL336230A1 (en) | 2000-06-19 |
US6028074A (en) | 2000-02-22 |
SK135699A3 (en) | 2000-05-16 |
KR20010006350A (ko) | 2001-01-26 |
HUP0002104A2 (hu) | 2001-01-29 |
NO995006D0 (no) | 1999-10-14 |
HUP0002104A3 (en) | 2002-03-28 |
AU733066B2 (en) | 2001-05-03 |
AU7090998A (en) | 1998-11-11 |
EP0975636B1 (en) | 2003-07-23 |
TR199902538T2 (xx) | 2000-02-21 |
CN1259951A (zh) | 2000-07-12 |
WO1998046606A1 (en) | 1998-10-22 |
IS5198A (is) | 1999-09-27 |
JP2001520645A (ja) | 2001-10-30 |
EP0975636A1 (en) | 2000-02-02 |
ATE245648T1 (de) | 2003-08-15 |
CA2286078A1 (en) | 1998-10-22 |
DE69816608T2 (de) | 2004-04-15 |
SE9701398D0 (sv) | 1997-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO995006L (no) | Nye forbindelser | |
NO20000311L (no) | Nye forbindelser | |
NO20000313L (no) | Nye forbindelser | |
NO993027L (no) | Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler | |
CA2272705A1 (en) | Fused bicyclic pyrimidine derivatives | |
SE9702001D0 (sv) | Novel compounds | |
GR3023825T3 (en) | Benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds | |
TR199800012T1 (xx) | Piroloprimidinler ve preparasyon i�in tatbikler. | |
NO20002788D0 (no) | Nye forbindelser | |
AP9901435A0 (en) | Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors. | |
CA2216535A1 (en) | Protein kinase c inhibitors | |
NO904694D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater. | |
CA2181175A1 (en) | Dihydro Pyrazolopyrroles | |
NO901684D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater. | |
NO903088L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater. | |
MX9702382A (es) | Nuevos derivados de pirimidona con actividad antifungica. | |
NO172537C (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-desmetyl-4-fluor-mevalonsyrederivater | |
NO167028C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrazolo(3,4-d)pyrimidinderivater | |
NO913644D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater. | |
NO984651L (no) | Anvendelse av benzonaftalenderivater for fremstilling av medikamenter for behandling av sykdommer i sentralnervesystemet | |
NO900972D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater. | |
NO900942D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater. | |
NO165544C (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 2,3-dihydro-1-(8-methyl-1,2,4-triazolo-(4,3-b)pyridazin-6-yl)-4(1h)-pyridinon. | |
FI933872A (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4-bensotriazepin-5(4H)-on-derivat | |
NO904470D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |